123 related articles for article (PubMed ID: 30485422)
21. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Harding K; Williams O; Willis M; Hrastelj J; Rimmer A; Joseph F; Tomassini V; Wardle M; Pickersgill T; Robertson N; Tallantyre E
JAMA Neurol; 2019 May; 76(5):536-541. PubMed ID: 30776055
[TBL] [Abstract][Full Text] [Related]
22. Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records.
McKay KA; Evans C; Fisk JD; Patten SB; Fiest K; Marrie RA; Tremlett H
Neuroepidemiology; 2017; 48(3-4):124-130. PubMed ID: 28683461
[TBL] [Abstract][Full Text] [Related]
23. Introduction: adherence to disease-modifying therapies--key to optimizing outcomes in relapsing multiple sclerosis.
Caon C; Saunders C; Smrtka J; Davis K; Davis A; Kay JM; Baxter N
J Neurosci Nurs; 2010 Oct; 42(5 Suppl):S1-4. PubMed ID: 21049827
[No Abstract] [Full Text] [Related]
24. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
[TBL] [Abstract][Full Text] [Related]
25. Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric?
Conway DS; Cecilia Vieira M; Thompson NR; Parker KN; Meng X; Fox RJ
Mult Scler J Exp Transl Clin; 2018; 4(2):2055217318777894. PubMed ID: 29854415
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
27. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
Hua LH; Fan TH; Conway D; Thompson N; Kinzy TG
Mult Scler; 2019 Apr; 25(5):699-708. PubMed ID: 29557704
[TBL] [Abstract][Full Text] [Related]
28. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis--a multicentre cohort study.
Grytten N; Aarseth JH; Espeset K; Berg Johnsen G; Wehus R; Lund C; Riise T; Haugstad R
Acta Neurol Scand Suppl; 2012; (195):51-7. PubMed ID: 23278657
[TBL] [Abstract][Full Text] [Related]
30. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
Teter B; Agashivala N; Kavak K; Chouhfeh L; Hashmonay R; Weinstock-Guttman B
Mult Scler; 2014 Jun; 20(7):830-6. PubMed ID: 24277325
[TBL] [Abstract][Full Text] [Related]
31. Predictors of adherence to Copaxone therapy in individuals with relapsing-remitting multiple sclerosis.
Fraser C; Hadjimichael O; Vollmer T
J Neurosci Nurs; 2001 Oct; 33(5):231-9. PubMed ID: 11668881
[TBL] [Abstract][Full Text] [Related]
32. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
Cascione M; Wynn D; Barbato LM; Pestreich L; Schofield L; McCague K
J Med Econ; 2013 Jul; 16(7):859-65. PubMed ID: 23647445
[TBL] [Abstract][Full Text] [Related]
33. Impact of diagnosis and early treatment on the course of multiple sclerosis.
Noyes K; Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
[TBL] [Abstract][Full Text] [Related]
34. Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmacies.
Bourdin A; Schluep M; Bugnon O; Berger J
Am J Health Syst Pharm; 2019 Jul; 76(15):1150-1157. PubMed ID: 31201774
[TBL] [Abstract][Full Text] [Related]
35. Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
Hernandez L; Guo S; Toro-Diaz H; Carroll S; Syed Farooq SF
J Med Econ; 2017 Mar; 20(3):228-238. PubMed ID: 27730845
[TBL] [Abstract][Full Text] [Related]
36. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.
Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S
Mult Scler Relat Disord; 2019 Aug; 33():13-21. PubMed ID: 31132664
[TBL] [Abstract][Full Text] [Related]
37. Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence.
Bruce JM; Bruce AS; Lynch S; Thelen J; Lim SL; Smith J; Catley D; Reed DD; Jarmolowicz DP
Psychopharmacology (Berl); 2018 Nov; 235(11):3303-3313. PubMed ID: 30244284
[TBL] [Abstract][Full Text] [Related]
38. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.
Macías-Islas MA; Soria-Cedillo IF; Velazquez-Quintana M; Rivera VM; Baca-Muro VI; Lemus-Carmona EA; Chiquete E
Acta Neurol Belg; 2013 Dec; 113(4):415-20. PubMed ID: 23670405
[TBL] [Abstract][Full Text] [Related]
39. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
Bsteh G; Feige J; Ehling R; Auer M; Hegen H; Di Pauli F; Deisenhammer F; Reindl M; Berger T
Mult Scler; 2017 Aug; 23(9):1241-1248. PubMed ID: 27765877
[TBL] [Abstract][Full Text] [Related]
40. Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
Fernández O; Duran E; Ayuso T; Hernández L; Bonaventura I; Forner M;
PLoS One; 2017; 12(10):e0185766. PubMed ID: 29049356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
